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Abstract: Acquired epilepsies can arise as a consequence of brain injury and result in unprovoked
seizures that emerge after a latent period of epileptogenesis. These epilepsies pose a major challenge
to clinicians as they are present in the majority of patients seen in a common outpatient epilepsy
clinic and are prone to pharmacoresistance, highlighting an unmet need for new treatment strategies.
Metabolic and homeostatic changes are closely linked to seizures and epilepsy, although, surprisingly,
no potential treatment targets to date have been translated into clinical practice. We summarize
here the current knowledge about metabolic and homeostatic changes in seizures and acquired
epilepsy, maintaining a particular focus on mitochondria, calcium dynamics, reactive oxygen species
and key regulators of cellular metabolism such as the Nrf2 pathway. Finally, we highlight research
gaps that will need to be addressed in the future which may help to translate these findings into
clinical practice.
Keywords: epilepsy; reactive oxygen species; mitochondria; Nrf2; calcium; cell death
1. Introduction
Epilepsy, a devastating disease, affects over 50 million people worldwide [1] and is defined by the
occurrence of unprovoked seizures. Most of these epilepsies are acquired as a consequence of a brain
injury and are followed by a latent period of epileptogenesis [2]. Once unprovoked seizures occur,
the patient is diagnosed with epilepsy and anticonvulsive treatment is initiated. Many patients
become seizure free with antiepileptic drugs, although approximately one third of patients
develop pharmacoresistant epilepsy [3], highlighting the unmet need for new treatment strategies.
Current anticonvulsants mainly act on neuronal voltage gated ion channels, whereas downstream
signaling cascades and non-neuronal cells are not targeted directly. However, the latter may be
instrumental in mediating pharmacoresistance and also epilepsy comorbidities. It is likely that
downstream signaling cascades such as metabolic and homeostatic cellular mechanisms contribute
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to epileptogenesis, fully established epilepsy and pharmacoresistant epilepsy, although the precise
mechanisms remain unclear.
There are clinical hints pointing to a strong involvement of mitochondria and bioenergetics in
epileptogenesis, seizures and epilepsy. For example, patients with mitochondrial mutations often
present with epilepsy as a phenotypic manifestation of the disease [4], highlighting the involvement of
mitochondrial dysfunction in epileptogenesis. In addition, seizure activity and epilepsy have been
linked to energy failure, which has been hypothesized to lead to neuronal injury responsible for
the clinical sequelae associated with epilepsy patients. The brain, which makes up only 2% of the
total bodyweight, contributes up to 20% to the resting whole body metabolism. This large metabolic
turnover is mainly due to synaptic transmission [5,6] where vesicle cycling consumes the majority
of presynaptic adenosine triphosphate (ATP) to mediate neuronal function [7]. Epileptiform activity
also induces large ionic conductances and depletes vesicular stores. Restoration of these changes, i.e.,
restoration of cellular homeostasis, is an energy demanding process [8]. Thus, it is not surprising
that ATP demand and production during seizures, epilepsy and particularly prolonged seizures,
such as those seen in status epilepticus, the maximum expression of epilepsy, is critical. It should
be noted though that mitochondria are not the only source of dysfunction in epileptic seizures, and
there are also other targets of homeostatic imbalances that occur during seizure activity. The most
prominent homeostatic changes during seizure activity include the accumulation of intracellular
calcium and the increased production of reactive oxygen species (ROS). Neuronal compromise during
seizure activity is dependent on intracellular Ca2+ entry [9]. There is accumulating evidence that
N-methyl-D-aspartate (NMDA) receptors play a pivotal role in intracellular Ca2+ accumulation during
seizure activity. This is supported by robust evidence showing that blocking of NMDA receptor activity
abolishes cell death both in vitro and in vivo [10–12]. NMDA receptor opening has also been shown
to promote ROS production via nicotinamide adenine dinucleotide phosphate (NADPH) oxidase,
an enzyme which has recently been drawn into the spotlight of seizure induced neuronal damage and
neuronal autophagy [13,14]. Excess ROS and Ca2+ are potent triggers of the mitochondrial permeability
transition pore opening, which is a key event and point of no return leading to mitochondrial swelling
and cytochrome c release from mitochondria, subsequently triggering the cell death cascade [15–17].
In this review, we summarize current knowledge about metabolic and homeostatic changes in
seizures and acquired epilepsy with a particular focus on mitochondria, Ca2+ dynamics, ROS and key
regulators of cellular metabolism such as the nuclear factor erythroid 2–related factor 2 (Nrf2)pathway.
It is not in the scope of this review to cover the extensive literature on genetic syndromes with
mutations in genes coding for mitochondrial proteins or key enzymes of metabolism, which has
been the subject of a number of other extensive reviews (e.g., [4,18]). Instead, we wish to focus on
patients suffering from acquired epilepsies (e.g., such as epilepsy due to hippocampal sclerosis) who
are frequently encountered in clinical practice and pose a challenge to practitioners given that 30%
present with pharmacoresistant seizures [3,19]. Finally, we highlight research gaps that will need to be
addressed in the future which may help to translate findings into clinical practice.
References for this review were identified through searches of PubMed with combinations of the
terms from keywords from the subsection titles (e.g., mitochondria) and “epilepsy” or “seizures” from
1950 until July 2017. In addition, manuscripts were also identified through searches of the authors’
own files and from reference lists of the articles pointed out by the PubMed searches. Due to space
restrictions, the final reference list was compiled from a selection of the articles identified which
were prioritized according to their originality and their ability to fit into the narrative style of the
current review.
2. Mitochondria and Epilepsy—Adenosine Triphosphate (ATP), Ca2+ and Cell Death
Mitochondria, initially coined bioblasts, were first described by Richard Altmann in 1890 and
were recognized to function as elementary organisms within the cell [20]. A further advance in their
functional characterization came through the introduction of new methods to study electron transport
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and metabolic states of the respiratory chain [21–24]. Peter Mitchell introduced the chemiosmotic
hypothesis of oxidative phosphorylation in 1961, linking energy metabolism to hydrogen transport
across the mitochondrial membrane [25]. Oxidative phosphorylation is the main source of ATP
generation in neurons since they lack powerful enzymes for glycolytic ATP production such as those
that are available in astrocytes [26].
The mitochondria are organelles that are amongst others essential in three different homeostatic
mechanisms. Firstly, their most prominent and obvious function is ATP production. Secondly, they are
involved in Ca2+ homeostasis through buffering of intracellular Ca2+, and thus have been referred
to as the “hub of Ca2+ signaling” [27]. Lastly, mitochondria are instrumental in apoptotic cell death
amongst others through the release of intramitochondrial cytochrome c [28]. Links to seizures and
epilepsy have been established for all three mechanisms.
2.1. ATP during Seizures and Epilepsy
Early pioneering experimental studies showed that glucose, ATP and other energetic substrates
decrease during seizure activity, particularly if this is prolonged [29–31]. This has been confirmed
on a cellular level, where ATP decrease during seizure activity has been shown in neurons [12].
Mitochondrial dysfunction and seizures have been closely linked to each other not only in epilepsies,
i.e., mitochondrial epilepsies, but are also increasingly recognized as a target in acquired epilepsy [18].
Anaplerosis, a strategy that aims to restore mitochondrial function through providing tricarboxylic
acid cycle substrates, has been recently advocated for use in acquired epilepsy [32]. The ketogenic diet,
a high fat diet used for the treatment of epilepsies, has been shown amongst other effects to upregulate
the neuronal expression of genes involved in the tricarboxylic acid cycle, oxidative phosphorylation
and glycolysis, along with improving mitochondria complex activities and boosting mitochondrial
biogenesis [33–36]. The ketogenic diet is particularly the treatment of choice in patients suffering from
seizures due to glucose transporter 1 (GLUT-1) deficiency syndrome and pyruvate dehydrogenase
complex deficiency, given that it circumvents the metabolic deficiencies in these syndromes [37].
However, the ketogenic diet has also been found to be an effective treatment in syndromes which
are not directly linked to mutations in the metabolic pathway, such as Dravet syndrome or Doose
syndrome [37,38] and has been advocated for the treatment of epilepsies due to mitochonridal
diseases [39]. The exact mechanisms of the seizure suppressive effect of the ketogenic remain elusive.
Beside its anaplerotic properties and its effect on mitochondria, direct anti-seizure effects of ketone
bodies, neurotransmitter and ion channel regulation as well as regulation of ROS amongst others have
been shown to play a role [36].
2.2. Mitochondria and Ca2+ Buffering in Seizures and Epilepsy
Besides ATP production, the most important function of mitochondria is the buffering of excess
Ca2+. Excess Ca2+ entry into neurons has been observed in rats that underwent status epilepticus
induced by bicuculline and L-allylglycine [9]. In these studies, mitochondrial Ca2+ overload has been
shown to lead to cell death and was particularly pronounced in CA1 and CA3 regions, which are
areas of the central nervous system (CNS) that are very susceptible to seizure induced cell death [9,40].
It is interesting that these very early studies already identified mitochondria as the main site of Ca2+
accumulation during prolonged seizures.
Different pathways for mitochondrial Ca2+ buffering have been described in the literature.
The mitochondrial uniporter (MCU), whose structure has been unraveled only recently [41], is the main
site of Ca2+ entry into the mitochondria and is thus instrumental in Ca2+ buffering during excess Ca2+
overload. The uptake and extrusion of Ca2+ in mitochondria is coupled to H+ and Na+ cycling that is
maintained by the electron transport chain, which creates a potential gradient across the mitochondrial
membrane [27,42] (Figure 1). Within the mitochondrial membrane, Ca2+ precipitates to insoluble Ca2+
phosphate complexes, a process which is dependent on the availability of phosphate. This in turn is
also dependent on the proton gradient and thus more phosphate enters the mitochondria if the gradient
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is higher, i.e., when the mitochondria are hyperpolarized. Ca2+ homeostasis through the MCU has been
shown to play a role during seizure activity. Inhibition of the MCU significantly attenuated neuronal
death after pilocarpine-induced status epilepticus and reduced levels of intracellular ROS [43].
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Figure 1. Ion circuits across mitochondrial and plasma membranes of a neuron. The figure shows a
schematic drawing of ion circuits across mitochondrial and plasma membranes of a neuron.
The respiratory chain is the driving force of these circuits either directly or indirectly by providing
adenosine triphosphate (ATP) for all ATP-dependent processes [44]. MCU: mitochondrial Ca2+
uniporter; ∆ψm: mitochondrial membrane potential; MP: membrane potential; NMDA-R:
N-methyl-D-aspartate receptor, AMPA-R: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
receptor; OMM: outer mitochondrial membrane; IMM: inner mitochondrial membrane; PMCA: plasma
membrane Ca2+ ATPase.
Mitochondrial permeability transition pore (MPTP) opening is another route for Ca2+ trafficking
across the mitochondrial membrane (Figure 2). The MPTP is a protein complex in the inner
mitochondrial membrane which has long been a mystery, but was recently found to be formed of two
ATP synthase (Complex V) dimers [45,46]. The importance of MPTP opening was soon recognized
in the triggering of apoptotic cell death through an increase in permeability of Ca2+ ions [16,46].
Our group has shown that seizure-induced cell death is partly mediated via MPTP opening as
treatment with cyclosporine A, a potent inhibitor of MPTP opening, was able to reduce mitochondrial
depolarization, the initial event leading to cell death during seizure activity [12]. More recently,
an interesting link between the MPTP and epilepsy treatment was made. Ketone bodies, which are
the main effectors of anti-seizure effects in the ketogenic diet and are a very effective anti-seizure
treatment, have been shown to mediate anti-seizure effects via MPTP modulation [47]. In this study,
mitochondria isolated from hippocampi of Kcna1-null mice with a genetic susceptibility to seizures
had a higher threshold for Ca2+ induced mitochondrial permeability transition if they were pre-treated
with ketone bodies.
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Figure 2. Mitochondrial permeability transition pore (MPTP) opening. Simplified model of the
mitochondrial permeability transition pore. Permanent opening of the permeability transition pore
leads to mitochondrial outer membrane permeabilization (MOMP). ADP: adenosine diphosphate;
Pi: phosphate group; ROS: reactive oxygen species. Reduced function of the respiratory chain,
as indicated with the red arrow (in B) subsequently leads to mitochondrial disintegration and release
of cytochrome c.
2.3. Cell Death, Mitochondria and Epilepsy
Early pioneering experiments by Meldrum and colleagues in baboons showed that brain seizure
activity can cause neuronal damage even in the absence of a systemic convulsion, showing that brain
damage is not only a secondary phenomenon wh ch occurs due to excessive muscle activation and
subsequent lactate acidosis [48]. That s izure activity itself can cause neuronal injury is now widely
accepted and it is appreciated that eve non-convulsive status epilepticus can be a life threatening
emergency that is often encountered in certain clinical settings such as the intensive care unit [49].
Mitochondria have now been put into the spotlight of seizure induced cell death. Continuous seizure
activity leads to ATP depletion and subsequent cell death [12,50]. Excess Ca2+ accumulation results in
mitochondrial swelling, permeability transition pore opening, activation of mitochondrial proteins
that trigger cell death (Bcl-2 family proteins Bax and Bok proteins [51]), release of cytochrome c,
activation of caspases which lead to mitochondrial permeability transition pore opening and loss of
mitochondrial outer membrane integ ity [16,52–56]. Abnormal mitoch ndri distribution, altered
mitochondrial motility, decreased mitochondrial membrane ot ntial, and diminished mitochondrial
respiration was observed in fibroblasts derived from two lethal encephalopathic patients with a loss of
function TRAK1 (trafficking of kinesin proteins 1) variant that was also shown to be associated with
seizures [57].
3. Excess Intracellular Ca2+ during Seizure Activity—The Endoplasmic Reticulum
Excess intracellular Ca2+ accumulation, which is one of the leading causes for seizure induced
sequelae, is an event that is not only governed by the interplay of Ca2+ entry through the plasma
membrane, but also by intracellular Ca2+ stores. An intracellular site of Ca2+ accumulation resides,
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as mentioned above, within the mitochondria. However, the endoplasmic reticulum (ER) has a larger
capability to store intracellular Ca2+ and thus is pivotal in Ca2+ homeostasis.
The ER, which was first identified as the site for intracellular Ca2+ release for muscle
contraction [58,59], was soon accepted to regulate Ca2+ homeostasis in cells other than muscle cells [60].
Inositol triphosphate (IP3) mediated mechanisms of Ca2+ release have been shown to play a role in
many neurological diseases [61].
With regards to epilepsy, surprisingly very few studies have examined the role of ER Ca2+
stores. Preincubation of neuronal hippocampal cultures with thapsigargin, a drug that depletes
intracellular ER Ca2+ stores, resulted in a decrease in the amount of neuronal excitation produced
by bicuculline [62]. Ictal discharges induced by pilocarpine or (RS)-3,5-dihydroxyphenylglycine in
hippocampal slices were dependent on internal Ca2+ stores as they were blocked by thapsigargin
or dantrolene, which both affect ER-Ca2+ stores [63]. A recent study showed that genetic silencing
of nitric oxide-induced activation of the ryanodine receptor, a receptor triggering Ca2+ release from
the ER, provides protection against cell death produced by kainate-induced status epilepticus [64].
This study highlights the importance of ER Ca2+ stores in mediating seizure-induced cell death.
In contrast to Ca2+ release from intracellular stores, extracellular Ca2+ entry has been identified as
the most important route of Ca2+ entry during seizure activity, which is supported by a plethora of
studies [11,12].
4. Ca2+ Channels and Transporters in the Plasma Cell Membrane and Their Role in
Epilepsy—NMDA Receptor, AMPA Receptor, VGCC and PMCA
The NMDA receptor (NMDA-R) forms a heterotetramer comprising two GluN1 and two GluN2
subunits and is mainly permeable by Na+ and Ca2+ ions. Depolarization of the cell opens the
channel by dislodging Mg2+ and Zn2+ ions from the pore [65]. The NMDA receptor has been
shown to be instrumental in seizure-induced neuronal death both in vitro [11,12] and in vivo [66,67].
The importance of NMDA receptors in epilepsy is underpinned by the fact that NMDA receptor
hyperactivation and upregulation of NMDA regulatory subunits is found in focal cortical dysplasia,
a highly epileptogenic lesion [68,69]. Ca2+ ions entering the cell upon NMDA receptor stimulation
have been shown to be responsible for subsequent cell death promoted by NMDA receptor activation,
since omission of Ca2+ ions from the extracellular solution mitigated the harmful NMDA receptor
mediated effects [11].
However, clinical evidence points to a more complicated role of NMDA receptors in epilepsy.
Antibodies against the extracellular N-terminal domain of the GluN1 subunit have been identified to
be responsible for NMDA receptor encephalitis [70,71], an antibody mediated disease which commonly
presents with seizures. It remains an unresolved paradox though, why reduction of surface NMDA
receptors as seen in anti-NMDA-R encephalitis leads to seizures. In this context, it is interesting
that, despite a dramatic clinical presentation of anti-NMDA-receptor encephalitis, including status
epilepticus, only a paucity of inflammatory markers and neuronal cell death have been observed,
which has repeatedly been confirmed in pathological brain specimens of affected patients [72–74].
Interestingly, mutations in subunits of the NMDA receptor, e.g., GRIN1 and GRIN2B, have recently
been identified as a cause of epileptic encephalopathy presenting with seizures [75,76]. In addition,
the NR1neo/neo mouse model of NMDA receptor hypofunction showed a dramatic sensitivity to
kainate induced seizures [77], highlighting the proconvulsant effect of NMDA receptor dysfunction.
It has been suggested that NMDA hypofunction may play a role in neurotoxicity during seizure
events [78].
Besides NMDA receptors, Ca2+ permeable AMPA receptors have been shown to play a role in
status epilepticus [79]. How substantial their contribution is to Ca2+ mediated injury in seizures
remains to be determined.
A review of the role of voltage gated Ca2+ channels (VGCC) channels is beyond the scope of
this review. It should just be mentioned though that T-type and P/Q-type channels contribute to
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epileptogenesis, modulation of network activity, and genetic seizure susceptibility [80]. These channels
have been linked to genetic forms of epilepsy and idiopathic epilepsy such as childhood absence
epilepsy. Rodent genetic models of absence epilepsy have revealed that CaV3.1 and CaV3.2 T-type
channel isoforms of VGCC are essential in the pathogenesis of absence epilepsy [81]. In addition,
subsequently these channels have also been shown to play a role in acquired epilepsy [82,83].
While NMDA receptors, Ca2+ permeable AMPA receptors and voltage gated Ca2+ channels
mediate the influx of Ca2+ into the cell, the plasma membrane ATPase (PMCA) together with the
sodium Ca2+ exchanger (NCX) removes Ca2+ from the cell against its concentration gradient (Figure 1).
A decrease of Ca2+-ATPase activities was found in pentylentetrazole treated rats [84]. The expression
of the Ca2+ extrusion proteins (PMCA and NCX) has been studied in a rat model of kainate-induced
status epilepticus [85]. This study found differences of PMCA and NCX isoform expression in neurons
and astrocytes in hippocampal formation during epileptogenesis. Decreased PMCA expression levels
have also been observed after status epilepticus [86]. The net effect on Ca2+ homeostasis in these
regions during epileptogenesis, however, was not assessed in these studies.
5. Epilepsy and Reactive Oxygen Species
ROS contribute to neuronal damage in a wide range of neurological diseases [87–89], including
seizures and epilepsy [90,91]. ROS include oxygen radicals such as superoxide, hydroxyl radicals,
and hydrogen peroxide (H2O2) molecules that are by-products of many biological reactions [92]. ROS in
excess cause cellular damage due to oxidation induced protein dysfunction and oxidation of DNA and
lipids. In an attempt to repair the cell’s DNA, repair enzymes such as the poly(ADP-ribose) polymerase
(PARP) excessively consumes ATP and thus stimulates cell death cascades through ATP depletion [93].
It is interesting in this context that PARP activation has recently been shown to contribute to status
epilepticus induced mitochondrial function [94]. Whether ROS or sources of ROS are active in the
upstream mechanisms of PARP activation has not been determined. ROS are also powerful enhancers
of mitochondrial permeability transition pore opening. By stimulation of IP3/ryanodine receptors,
sarco/endoplasmic reticulum Ca2+-ATPase pump inhibition and inhibition of plasma membrane Ca2+
channels, ROS increase intracellular Ca2+ levels, which together with ROS, then trigger mitochondrial
permeability transition [46] (Figure 2). ROS can also directly interact with membrane lipids triggering
lipid peroxidation. This process affects polyunsaturated lipids and increases the instability of the cell
membrane [95]. The brain with its high content of polyunsaturated fatty acids is particularly prone to
such damage [89].
There is overwhelming evidence supporting a role for ROS in epilepsy [96]. Early studies
have investigated brain homogenates [97], whereas with advances in ROS imaging techniques,
more sophisticated real time experiments could be performed allowing more detailed cellular
analyses [13,98]. Despite this prominent role of ROS in cell homeostasis and in the triggering of
mitochondrial dysfunction, previous results of antioxidant therapy in neurologic disease have been
mixed. This is most likely due to a lack of characterization of the sources of free radical production
and insight into mechanisms of antioxidant protection of the compounds used in these trials [99].
5.1. Mitochondria and ROS in Seizures and Epilepsy
Traditionally, mitochondria have been assumed to be the main site of ROS production during
seizure activity. Some of this has been initially concluded by the coincidence of mitochondrial
membrane depolarization, cellular ROS increases and cellular damage [98]. Complex III has been
proposed to be a site of ROS production during seizures, which is based on findings from isolated
mitochondria [90]. Using a mitochondria specific ROS probe, we were unable to demonstrate that ROS
originate from the mitochondria during seizure like activity at least in the first few minutes of seizure
activity [13]. Thus, the exact contribution of mitochondrial ROS to the overall ROS burden during
seizures remains to be determined.
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A more recent study analyzed hippocampal and parahippocampal tissue samples from 74 patients
with drug-refractory temporal lobe epilepsy and found that neuropathological signs of inflammation
in patients suffering from hippocampal sclerosis correlated with mitochondrial DNA (mtDNA)
mutations [100]. This finding supports the hypothesis that chronic inflammation leads to mitochondrial
dysfunction by ROS-mediated mtDNA mutagenesis, which promotes epileptogenesis and neuronal cell
loss in patients suffering from mesial temporal lobe epilepsy due to hippocampal sclerosis. This study
is interesting since it draws attention to inflammatory ROS. In this model, mitochondria are the targets
of ROS induced mutagenesis, with mitochondrial dysfunction occurring as a secondary effect.
5.2. NADPH Oxidase Derived ROS and Epilepsy
NADPH oxidase was discovered by studying the respiratory burst in phagocytes and
granulocytes [101]. Subsequently, NADPH oxidase expression has been documented in many tissues.
There is accumulating evidence highlighting the importance of NADPH oxidase, particularly the isoform
NOX2 and NOX4, in brain disease [13,102]. In mammals, seven NADPH isoforms known as NOX1,
NOX2, NOX3, NOX4, NOX5, dual oxidase (DUOX1) and DUOX2 have been documented [103,104].
NOX1, NOX2, NOX3 and NOX4 expression has been shown in neurons. NOX4 was demonstrated to
play a major role in astrocytes, although NOX2 and NOX1 expression has also been documented [105].
Phagocytes were the cell type that fuelled the discovery of the NADPH oxidase [106]. Thus, besides neurons
and astrocytes, microglia, the resident phagocytes of the CNS, unsurprisingly represent a prominent
cell type that shows NADPH oxidase activity upon activation [107]. Oligodendrocytes are the only
neural cells that do not express NADPH oxidase [104]. Amongst non-neural cells in brain tissue,
endothelial cells or pericytes show high expression of NOX4 [108]. In fact, endothelial cells have been
shown to be the main site of NOX4 expression [109].
NOX2 has been highlighted to play a role in seizures and epilepsy. This is not surprising since
NMDA receptor activation, which has a leading role in epilepsy, has been found to trigger NOX2
assembly and activity [110,111]. We and others have found significant activation of NOX2 during
seizure activity and suppression of this enzyme was effective in reducing seizure induced cell death
in various epilepsy models [13,112–114]. Moreover, NOX2 seems to be involved in status epilepticus
induced hypotension since NOX2 was found to be upregulated in the rostral ventrolateral medulla,
a key nucleus of the baroreflex loop, which mediated status epilepticus-induced hypotension [115].
In addition, NADPH oxidase was also found to be involved in the vasogenic edema formation during
status epilepticus [116]. Analyses of human tissue showed that NOX2 was upregulated in surgical
hippocampal specimens from a patient suffering from pharmacoresistant seizures, highlighting that
NADPH oxidase plays a role in acquired epilepsy [117]. Table 1 summarizes studies that have looked at
the role of NADPH oxidase in epilepsy. It should be noted that some of the studies on the involvement
of NADPH oxidase in epilepsy used non-subtype specific NADPH oxidase inhibitors such as apocynin
and AEBSF (4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride) and thus, no conclusion on the
isoforms of NADPH oxidase activation can be drawn [14,118]. In addition, there is a lack of studies on
knock out animals, which would definitely add to the current evidence.
With regards to the other NADPH oxidase isoforms, besides NOX2, NOX4 has been highlighted
as a major source of ROS in acute brain diseases such as stroke [102]. NOX4 is mainly located within
intracellular organelles and produces superoxide that is rapidly dismutated into H2O2 [103]. We have
previously shown that NOX2 produces ROS during seizure activity [13], yet NOX2 is particularly active
in the early stages of seizure activity. It remains unclear whether other sources of ROS production are
involved particularly in later stages of seizure activity, i.e., beyond the first few minutes. We have
previously shown that energy depletion and impaired mitochondrial function occurs particularly in
prolonged seizure activity [12]. In this context, NOX4-derived ROS are particularly interesting because
of the interaction of NOX4 with mitochondrial function and its expression within mitochondrial
membranes [119,120].
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Table 1. Studies on the role of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase in seizures and epilepsy.
Study Species Epilepsy Model(In Vivo/Ex Vivo/In Vitro)
NADPH Oxidase
Subtype Studied NADPH Oxidase Inhibition Main Findings
Zhu et al.,
2016 [14] Mouse
Pentylenetetrazol (PTZ) model
(in vivo) No
Pharmacological
(Apocynin)
- Kindling induces NADPH dependent ROS production accompanied by mitochondrial
ultrastructural damage
- Pharmacological inhibition of NADPH oxidase by apocynin suppressed hippocampal
autophagy in the PTZ model
Williams et al.,
2015, [118] Rat
Perforant path stimulation (PPS)
model (ex vivo and in vivo) No
Pharmacological
(AEBSF)
- ROS are upregulated and glutathione levels are downregulated in chronic epilepsy
- ROS induced cell death in epilepsy can be blocked with NADPH oxidase inhibition
with AEBSF
Pecorelli et al.,
2015, [117] Human
Tissue from Patients with drug
resistant epilepsy (ex vivo) Yes (NOX2) N/A - p47(phox) and p67(phox) (NOX2) expression in epileptic hippocampus
Kovac et al.,
2015 [13] Rat Low magnesium model (in vitro) Yes (NOX2)
Pharmacological
(AEBSF, gp-91-tat)
- ROS were generated primarily by NADPH oxidase and later Xanthine oxidase
- Inhibition of NADPH or xanthine oxidase reduced seizure-like activity-induced
neuronal apoptosis
Kim et al.,
2013, [116] Rat Pilocarpine induced SE (in vivo) Yes (NOX2)
Pharmacological
(Apocynin)
- Vasogenic edema in SE is mediated via tumor necrosis factor-α (TNF-α) stimulated
endothelin-1 (ET-1) release and subsequent endothelial nitric oxide synthase and NADPH
oxidase activation
- Inhibition of NADPH oxidase attenuated SE induced vasogenic edema
Kim et al.,
2013, [112] Rat
Pilocarpine induced epilepsy (ex
vivo and in vivo) Yes (NOX2)
Pharmacological
(Apocynin)
- Pilocarpine-induced seizure increased NOX2 expression in the plasma membrane of
hippocampal neurons at 12 h post-insult
- Apocynin treatment prevented this increase
Tsai et al.,
2012, [115] Rat
SE due to focal temporal injection
of kainic acid (TLSE; ex vivo and
in vivo)
Yes (NOX2) Pharmacological(Apocynin)
- p47phox (NOX2) is upregulated in the rostral ventrolateral medulla, a key nucleus of the
baroreflex loop, which mediated SE induced hypotension
- Pretreatment with apocynin by microinjection reduced baroreflex-mediated sympathetic
vasomotor tone in an experimental model of temporal lobe status epilepticus
Di Maio et al.,
2011, [114] Rat
Pilocarpine induced seizures
(in vitro and ex vivo) Yes (NOX2)
Pharmacological
(Apocynin,
6-amino-nicotidamid)
- Apocynin and 6-aminonicotidamid were able to prevent thiol oxidation in vitro
- p47phox (NOX2) redistribution to the neuronal cell membrane was seen after pilocarpine
treatment (ex vivo)
Pestana et al.,
2010, [91] Rat Pilocarpine induced SE (in vivo) No
Pharmacological
(Apocynin) - Apocynin inhibited ROS production and cell death in CA1 and CA3 areas
Patel et al.,
2005, [113] Rat Kainate model of epilepsy (ex vivo) Yes (NOX2) N/A
- Kainate-induced seizures result in the translocation of gp91phox (NOX2) and increased
NADPH-driven superoxide production in hippocampal membranes
ROS: reactive oxygen species; NOX2: NADPH Oxidase Subtype 2; CA1 and CA3: hippocampal regions: cornu ammonis 1 and cornu ammonis 3.
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5.3. Other Sources of ROS in Epilepsy
Other sources of ROS have been described in seizures and epilepsy, including xanthine oxidase,
cyclooxygenase and lipoxygenase [13,96,121,122]. Xanthine oxidase, an enzyme involved in the
catabolism of purines, may be an important source of ROS production during prolonged seizures since
breakdown of ATP enhances xanthine oxidase activity. The exact contribution of these sources to ROS
production during seizures and epilepsy remains unknown, but it is likely that they are not the main
ROS producers in these conditions.
One strategy to decrease the ROS burden during seizure activity is to reduce ROS production by
blocking key enzymes; another strategy is to boost ROS scavengers. With regards to the latter, the Nrf2
pathway represents an ideal target.
6. Key Regulators of Energy Metabolism and ROS—A Focus on Nrf2 in Seizures and Epilepsy
Nrf2 is a transcription factor that has been shown to regulate both antioxidant defense and
intermediary metabolism and thus combines some of the mechanisms outlined above [123–126]. One of
its main negative cytoplasmic regulators is Kelch-like ECH associated protein 1 (KEAP1). KEAP1 is
responsible for ubiquitination and proteosomal degradation of Nrf2 and thus tightly controls its
activity [127–129]. Nrf2 is a potential drug target and there are powerful small molecule inducers that
activate Nrf2 by chemically modifying cysteine sensors of KEAP1 or disrupt KEAP1 binding [130–133].
Some of these small molecule Nrf2 inducers, such as RTA408, are currently being investigated in
clinical trials for the treatment of mitochondrial myopathy and Friedreich’s ataxia (Avaliable online:
https://clinicaltrials.gov). Moreover, dimethyl fumarate, a drug licensed for use in multiple sclerosis,
is an Nrf2 inducer [134], and thus this drug would lend itself to repurposing. Binding of these small
molecules to KEAP1 leads to Nrf2 stabilization and translocation to the nucleus where it binds as
a heterodimer with a small Maf transcription factor to the antioxidant response element, a specific
DNA sequence in the promoter of Nrf2 target genes. This then stimulates transcription of antioxidant
proteins such as glutathione-S-transferases (GSTs), NAD(P)H:quinone oxidoreductase 1 (NQO1) as
well as enzymes involved in glutathione biosynthesis and regeneration [135,136]. Interestingly Nrf2
also controls mitochondrial function by enhancing substrate availability [124]. In addition, it has
been reported that treatment of rats with the pharmacological Nrf2 activator sulforaphane promotes
resistance of liver mitochondria to redox-regulated MPTP opening [137]. More recently, we have also
highlighted an important interaction between NADPH oxidase expression and the Nrf2 pathway
where different expression patterns of NOX4 were seen in neuronal cultures with constitutively active
Nrf2 in comparison to Nrf2-knockout cells and controls [138]. All these mechanisms of action render
Nrf2 an attractive target to treat seizures.
Nrf2 has been highlighted as a target in the treatment of seizures and epilepsy [96,139]. One of
the first descriptions of a protective effect of Nrf2 on seizures and epilepsy came from Mazzuferi
and colleagues [140]. They screened biosets from epilepsy-related studies and identified Nrf2 as an
important transcription factor in epilepsy. They then showed that Nrf2 mRNA expression is increased
in human epileptic tissue and in murine brain tissue after status epilepticus. Adeno-associated
virus mediated-overexpression of Nrf2 reduced the frequency and duration of seizures induced by
pilocarpine in mice. Several studies with small molecule enhancers, i.e., Nrf2 inducers, have been
performed. Daily injections of sulforaphane for five days elevated the seizure thresholds to 6 Hz
stimulation and fluorothyl-induced seizures. In addition, it protected mice against pilocarpine-induced
status epilepticus, demonstrating its efficacy in various epilepsy models [141]. Sulforaphane also
suppressed the progression of amygdala kindling, and also ameliorated the cognitive impairment
induced by epileptic seizure [142]. An interesting approach was chosen in a recent study by Pauletti
and colleagues [143] where they combined the Nrf2 inducer sulforaphane with N-acetylcysteine
treatment with the rationale that these mechanisms are complementary in increasing glutathione
levels, as glutathione is one of the main intracellular antioxidants and thus one of the most potent ROS
scavengers within the brain. Sulforaphane at high doses (>100 mg/kg) was shown to lead to sedation,
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hypothermia, impairment of motor coordination, decrease in skeletal muscle strength, and deaths
in addition to offsite effects such as leucopenia [144]. It should be noted, however, that such high
concentrations are not necessary for Nrf2 activation and were not administered in the studies that
showed a protective effect of sulforaphane. These studies largely used a dose of 5 mg/kg. In addition,
efforts are underway to develop highly potent blood–brain barrier permeable Nrf2 inducers and some
of the currently available inducers as omaveloxolone (RTA408) have been developed in an attempt to
increase blood–brain barrier permeability [145].
Figure 3 summarizes metabolic and homeostatic changes during seizures and epilepsy and the
pathways that can be targeted to ameliorate these changes.
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cell death during seizure activity. We have outlined some ideas about the sources of ROS involved
in this process. However, the precise sources of ROS involved remain a matter of debate. It is likely
that different sources are active at different time points during seizures and epilepsy, such as has been
shown in other diseases, e.g., stroke [146]. With regards to this, we think that investigations into the
role of the NADPH oxidase with a focus on the different subtypes is pressing, and such investigations
are ideally performed in knock out animals, since current evidence on the role of NADPH oxidase
in seizures and epilepsy relies on pharmacological manipulation. This is difficult since NADPH
oxidase inhibitors are rarely isoform selective and often not even NADPH oxidase specific [147].
As outlined above, NADPH oxidase isoform expression varies between different brain resident cells,
thus another pertinent question is to what extent different cell types contribute to ROS formation
during seizure activity. Finally, the Nrf2 pathway has been highlighted as an important pathway that
is at the interface of redox and intermediary metabolism within the cell. Nrf2 activation boosts ROS
scavengers, but was more recently found to have an effect on ROS producing enzymes such as the
NADPH oxidase. Further characterization of this interaction will help to design ideal drug targets and
allow for combinations of approaches such as have been recently advocated [143] to combat seizure
induced ROS. These are one of the main events leading to cell death and continuous seizures during
seizure activity and thus contribute to epilepsy and epilepsy comorbidities.
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